Lion's Mane and Cancer
5-FU exceeded in some GI cancer cell line assays by lion's mane extract (Li et al., 2014)
Li and colleagues (2014) tested lion's mane extracts against human gastrointestinal cancer cell lines and xenograft tumors, finding anticancer activity that in some assays exceeded 5-fluorouracil, a standard chemotherapy drug. This is the most compelling single finding in lion's mane cancer research, and it comes from cell line and mouse data, not a human trial.
Li et al., Journal of Ethnopharmacology, 2014
PI3K/AKT
signaling pathway through which Hericium erinaceus extract induces apoptosis in prostate cancer cells (Atmaca et al., 2024), the most recent cancer-specific mechanism study
0 human trials
no randomized controlled trial has tested lion's mane against cancer in human patients; Menon 2025 systematic review confirms all direct cancer evidence is preclinical
2 compound classes
erinacine terpenoids and beta-glucan polysaccharides have distinct anti-cancer mechanisms; erinacines target oncogenic signaling pathways; polysaccharides activate immune-mediated tumor killing
Li et al., Journal of Ethnopharmacology, 2014
View as image ↗The research on lion's mane and cancer needs to start with an honest statement about what type of evidence exists: laboratory studies using cancer cell lines and animal xenograft models. No randomized controlled trial has tested lion's mane against cancer in human patients. That does not make the preclinical evidence uninteresting. It makes it exactly what it is: a biological proof of concept that specific lion's mane compounds interact with cancer-relevant molecular targets in ways that reduce tumor cell survival in controlled laboratory conditions.
Whether that translates to clinical benefit in humans is the unanswered question. The preclinical evidence is scientifically grounded and mechanistically specific. Treating it as evidence of clinical efficacy would be premature. Dismissing it because it is preclinical would miss what the evidence actually shows. For the broader context of what lion's mane is and does, see what is lion's mane mushroom: a science-based overview.
Key Takeaways
- Li and colleagues (2014) tested lion's mane extracts against human gastrointestinal cancer cell lines and xenograft tumors; some preparations showed antiproliferative activity that exceeded 5-fluorouracil (5-FU) in specific cell line assays, alongside significant xenograft tumor inhibition
- Lion's mane has two distinct compound classes with different anti-cancer mechanisms: erinacine terpenoids inhibit oncogenic signaling pathways (Prasher et al., 2023), while polysaccharides activate immune-mediated tumor killing and directly inhibit cancer cell proliferation (He et al., 2017)
- Atmaca and colleagues (2024) identified that H. erinaceus extract induces apoptosis in prostate cancer cells specifically through PI3K/AKT and RAS/MAPK pathway inhibition, the newest cancer-specific mechanistic evidence
- Gastric cancer, colorectal cancer, and hepatocellular carcinoma have the strongest dedicated preclinical evidence base; prostate cancer is the newest addition to the studied tumor types
- Gravina and colleagues (2023) documented H. erinaceus's role in gastrointestinal diseases in a comprehensive historical and mechanistic review, confirming its relevance to GI cancer in the context of its broader GI tract effects
- Menon and colleagues' 2025 systematic review of H. erinaceus supplementation confirmed no serious safety concerns in the existing human evidence base, providing indirect safety context even without direct cancer trial data
The Honest Evidence Level: What "Preclinical" Means
Cell line studies take cancer cells grown in laboratory dishes and expose them to compounds, measuring whether cancer cells die, stop dividing, or change behavior. These studies are useful for identifying mechanisms and prioritizing compounds for further research. They are not predictive of human clinical outcomes: compounds that kill cancer cells in dishes routinely fail in clinical trials because of bioavailability, metabolism, dose requirements, and tumor microenvironment factors that dish experiments cannot replicate.
Xenograft studies implant human cancer cells into immunocompromised mice and test whether treatments shrink the resulting tumors. These are more predictive than cell line studies but still represent an intermediate evidence level. The Menon 2025 systematic review of H. erinaceus supplementation confirms that no cancer-specific human clinical trials have been conducted with lion's mane as the study intervention.[2]
This is the honest starting point for reviewing lion's mane cancer research. The studies below describe real biological effects at the cellular and animal level. They do not demonstrate clinical efficacy in human cancer patients.
Two Compound Classes, Two Different Anti-Cancer Mechanisms
Lion's mane contains two structurally distinct classes of bioactive compounds, and they suppress cancer through different pathways.
Erinacine terpenoids (primarily from the mycelium) act at the level of oncogenic signaling. Prasher and colleagues (2023) published a focused analysis of the oncologic pathways that erinacine A inhibits.[1] Erinacine A inhibits NF-kB activation, one of the central signaling nodes in cancer cell survival and inflammatory promotion of tumor growth. It induces apoptosis (programmed cell death) in cancer cells through mitochondrial pathways. It reduces the expression of pro-survival proteins in the BCL-2 family that cancer cells hijack to avoid death. Each of these targets is a validated oncologic pathway that pharmaceutical compounds also attempt to reach.
Beta-glucan polysaccharides (from both the mycelium and fruiting body) act primarily through immune activation and direct antiproliferative effects. He and colleagues (2017) reviewed the biological activities of H. erinaceus polysaccharides comprehensively, documenting antiproliferative activity against multiple cancer cell lines and immune stimulation effects that enhance natural killer cell and macrophage activity against tumor cells.[5] The polysaccharide mechanism is additive to the terpenoid mechanism: one acts directly on cancer cells' survival signaling, the other activates the immune system to eliminate cancer cells.
This two-pathway framework distinguishes lion's mane from single-mechanism natural compounds and explains why different extraction methods produce different activity profiles.
The Li 2014 Study: The Most Compelling Single Data Point
Li and colleagues (2014) conducted the most cited and mechanistically specific study of lion's mane against gastrointestinal cancers.[3]
The study tested H. erinaceus extracts against multiple human gastrointestinal cancer cell lines including gastric cancer, colorectal cancer, and hepatocellular carcinoma. The primary findings:
In cell line assays, lion's mane extracts inhibited cancer cell proliferation with IC50 values (the concentration needed to inhibit 50% of cell growth) in ranges comparable to and in some preparations exceeding those of 5-fluorouracil (5-FU), a frontline chemotherapy agent used in GI cancer treatment.
In xenograft experiments (tumors established in immunocompromised mice), treatment with lion's mane extract produced significant tumor inhibition compared to untreated controls.
The 5-FU comparison is the data point absent from every competitor article. It is not a claim that lion's mane is as good as 5-FU in clinical practice; it is a statement about relative potency in controlled laboratory conditions, where the compounds were tested under identical conditions against the same cancer cells. Laboratory potency and clinical efficacy are different measures. But for establishing that lion's mane's anti-cancer activity is not trivial, the 5-FU comparison in GI cancer cell lines is the strongest single piece of data in the preclinical evidence base.
Prostate Cancer: The PI3K/AKT Mechanism (2024)
Atmaca and colleagues (2024) added prostate cancer to the list of tumor types with documented lion's mane preclinical evidence, and identified a specific mechanistic pathway.[7]
Their study tested H. erinaceus extract against prostate cancer cell lines and found dose-dependent apoptosis induction. The mechanistic investigation identified the PI3K/AKT and RAS/MAPK signaling pathways as the specific routes through which the extract induced cancer cell death.
PI3K/AKT is one of the most frequently activated signaling pathways in human cancers, including prostate cancer. Multiple pharmaceutical companies have developed PI3K inhibitors targeting this pathway. The finding that H. erinaceus extract inhibits this pathway in prostate cancer cells means it is engaging a clinically validated oncologic target through a mechanism that has pharmaceutical precedent.
RAS/MAPK is a separate but related pathway involved in cancer cell proliferation and survival. Its simultaneous inhibition alongside PI3K/AKT suggests lion's mane extract engages multiple cancer signaling nodes, consistent with the multi-mechanism picture established by the erinacine compound analysis.
Where the Cancer Evidence Is Strongest: A Type-by-Type Overview
The preclinical evidence base is not equal across cancer types. Based on the study record:
Gastrointestinal cancers (gastric, colorectal, hepatocellular): The most evidence. Li 2014 tested multiple GI cancer lines with positive results. Gravina and colleagues (2023) reviewed H. erinaceus specifically in GI diseases, providing historical and mechanistic context for the GI tract focus.[6] The traditional use of lion's mane in East Asian medicine specifically for gastric conditions aligns with the preclinical evidence concentration.
Prostate cancer: One dedicated study (Atmaca 2024) with specific PI3K/AKT mechanistic data. More focused than the GI evidence but mechanistically specific for a validated oncologic pathway.
Breast cancer, lung cancer, leukemia: Ghosh and colleagues (2021) reviewed the broader medicinal properties of lion's mane across conditions, including mentions of antiproliferative activity against these tumor types from various cell line studies.[4] The evidence for these cancer types is less concentrated than for GI cancers.
The overall pattern: lion's mane compounds show activity against cancer cells generally (consistent with their mechanisms targeting pathways shared across cancer types), with GI cancers having the deepest dedicated study program.
What the Evidence Gap Means for Cancer Patients
No oncologist in the United States would prescribe lion's mane as a cancer treatment, and no licensed claim exists because no evidence at the required standard exists. This is not a failure of the compound; it is an accurate description of where the research currently stands.
The absence of human trials reflects resource allocation, not lack of interest. Human cancer trials require FDA Investigational New Drug applications, Phase I safety trials, Phase II efficacy trials, and Phase III comparative trials. This process costs hundreds of millions of dollars. No pharmaceutical company has pursued this path for lion's mane because the compound cannot be patented in its natural form, eliminating the commercial incentive structure that funds pharmaceutical development.
What does exist: a mechanistically credible body of preclinical work showing that lion's mane compounds engage multiple validated oncologic targets, produce tumor cell death through apoptosis and pathway inhibition, and show xenograft tumor inhibition in animal models. This is a meaningful scientific foundation. The clinical translation question remains open.
The Bottom Line
Lion's mane has preclinical cancer evidence across multiple tumor types: Li 2014 found GI cancer cell line activity exceeding 5-FU in some assays plus xenograft tumor inhibition; Atmaca 2024 identified PI3K/AKT and RAS/MAPK apoptosis induction in prostate cancer cells; Prasher 2023 mapped erinacine A's oncologic pathway inhibition including NF-kB, BCL-2, and mitochondrial apoptosis. He 2017 documented polysaccharide antiproliferative activity through immune activation. No human cancer clinical trial has been conducted with lion's mane as the study intervention; Menon 2025 systematic review confirms the absence of human cancer trial data.
Frequently Asked Questions
Sources & References
- 1RTHM-01769·Prasher, Parteek et al. (2023). “Key oncologic pathways inhibited by Erinacine A: A perspective for its development as an anticancer molecule..” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.Study breakdown →PubMed →↩
- 2RTHM-00943·Menon, Arya et al. (2025). “Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review..” Frontiers in nutrition.Study breakdown →PubMed →↩
- 3RTHM-00614·Li, Guang et al. (2014). “Anticancer potential of Hericium erinaceus extracts against human gastrointestinal cancers..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
- 4RTHM-00687·Ghosh, Sandipta et al. (2021). “Prospecting medicinal properties of Lion's mane mushroom..” Journal of food biochemistry.Study breakdown →PubMed →↩
- 5RTHM-00472·He, Xirui et al. (2017). “Structures, biological activities, and industrial applications of the polysaccharides from Hericium erinaceus (Lion's Mane) mushroom: A review..” International journal of biological macromolecules.Study breakdown →PubMed →↩
- 6RTHM-01700·Gravina, Antonietta Gerarda et al. (2023). “Hericium erinaceus, a medicinal fungus with a centuries-old history: Evidence in gastrointestinal diseases..” World journal of gastroenterology.Study breakdown →PubMed →↩
- 7RTHM-01853·Atmaca, Harika et al. (2024). “Hericium erinaceus Extract Induces Apoptosis via PI3K/AKT and RAS/MAPK Signaling Pathways in Prostate Cancer Cells..” Chemistry & biodiversity.Study breakdown →PubMed →↩